Full Text View
Tabular View
Study Results
Related Studies
Ezetimibe/Simvastatin (10 mg/40 mg) vs. the Doubling of Atorvastatin in High Risk Participants (MK-0653A-134 AM1)(COMPLETED)
This study has been completed.
Study NCT00782184   Information provided by Merck

First Received on October 29, 2008.   Last Updated on September 22, 2011   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypercholesterolemia
More general conditions related to this trial
Dyslipidemias
Hyperlipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Interventions listed in this trial
ezetimibe/simvastatin 10/40
atorvastatin 40 mg
atorvastatin 20 mg
Additional drug interventions recognized in this trial
Atorvastatin
Ezetimibe
Simvastatin
More general drug interventions related to this trial
Anticholesteremic Agents
Antimetabolites
Enzyme Inhibitors
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Hypolipidemic Agents
Lipid Regulating Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Merck


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services